Ibrutinib‐associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins-Reference-Cited by-同舟云学术

Ibrutinib‐associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins

Published:2019-08-22 Issue:11 Volume:94 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Ambinder Alexander J.¹^ORCID,Hambley Bryan¹,Shanbhag Satish¹^ORCID,Merrill Samuel A.¹²

Affiliation:

1. Division of Hematology, Department of MedicineJohns Hopkins University School of Medicine Baltimore Maryland

2. West Virginia University Cancer InstituteWest Virginia University School of Medicine Morgantown West Virginia

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25611

Reference15 articles.

1. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

2. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Imbruvica NDA 210563/Orig2s000 approval letter.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210563Orig1s000 210563Orig2s000TOC.cfm. Published February 16 2018. Accessed April 24 2019.

3. Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome

4. Flow Cytometric Findings in Hemophagocytic Lymphohistiocytosis

5. “Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Case of Chronic Lymphocytic Leukemia Complicated by Hemophagocytic Lymphohistiocytosis: Identifying the Aberrant Immune Response;Journal of General Internal Medicine;2022-02-17

2. Ibrutinib plus rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia: a safety evaluation;Expert Opinion on Drug Safety;2021-08-11

3. Multiple drugs;Reactions Weekly;2019-11